204 related articles for article (PubMed ID: 21337318)
1. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.
Gutierrez-Roelens I; Galant C; Theate I; Lories RJ; Durez P; Nzeusseu-Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheum; 2011 May; 63(5):1246-54. PubMed ID: 21337318
[TBL] [Abstract][Full Text] [Related]
2. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
3. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
6. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.
Koenders MI; Marijnissen RJ; Joosten LA; Abdollahi-Roodsaz S; Di Padova FE; van de Loo FA; Dulos J; van den Berg WB; Boots AM
Arthritis Rheum; 2012 Jun; 64(6):1762-70. PubMed ID: 22213107
[TBL] [Abstract][Full Text] [Related]
7. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
[TBL] [Abstract][Full Text] [Related]
8. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
[TBL] [Abstract][Full Text] [Related]
9. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab.
Hogan VE; Holweg CT; Choy DF; Kummerfeld SK; Hackney JA; Teng YK; Townsend MJ; van Laar JM
Ann Rheum Dis; 2012 Nov; 71(11):1888-94. PubMed ID: 22736099
[TBL] [Abstract][Full Text] [Related]
11. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis.
Rosengren S; Wei N; Kalunian KC; Kavanaugh A; Boyle DL
Rheumatology (Oxford); 2011 Mar; 50(3):603-10. PubMed ID: 21098574
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
[TBL] [Abstract][Full Text] [Related]
13. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity.
Kormelink TG; Tekstra J; Thurlings RM; Boumans MH; Vos K; Tak PP; Bijlsma JW; Lafeber FP; Redegeld FA; van Roon JA
Ann Rheum Dis; 2010 Dec; 69(12):2137-44. PubMed ID: 20679475
[TBL] [Abstract][Full Text] [Related]
14. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
15. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
16. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
[TBL] [Abstract][Full Text] [Related]
17. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients.
Wijbrandts CA; Remans PH; Klarenbeek PL; Wouters D; van den Bergh Weerman MA; Smeets TJ; Vervoordeldonk MJ; Baeten D; Tak PP
Arthritis Rheum; 2008 Nov; 58(11):3330-9. PubMed ID: 18975323
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints.
Polzer K; Baeten D; Soleiman A; Distler J; Gerlag DM; Tak PP; Schett G; Zwerina J
Ann Rheum Dis; 2008 Nov; 67(11):1610-6. PubMed ID: 18174217
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
